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3p deletions and telomerase reactivation are two of the most frequent events described in relation to non-small-cell lung cancer
(NSCLC) pathogenesis. Moreover, a number of genes that map on 3p have been proposed as candidates to tumour-suppressor
genes of importance in the lung cancer process. In this work, we analysed deletions at different 3p loci in relationship to telomerase
activity in 66 NSCLCs obtained from patients who had suffered potentially curative surgery. Also, we evaluated prognostic
implications. DNA samples were analysed for 3p deletions using five different polymorphic human dinucleotide repeat DNA markers
(D3S1619 at 3p22.2, D3S3623 at 3p22.1, D3S1260 at 3p21.33, D3S3697 at 3p14.3, and D3S3722 at 3p21.2). Telomerase activity
was investigated by a TRAP-based method. Possible correlations between the different molecular markers and distributions of
disease-free survival were estimated. Our data revealed a significant correlation between telomerase activity and losses of
heterozygosity (LOH) on D3S3697 (P¼0.040), since all of the tumours showing deletion at this locus were positives for telomerase.
Moreover, our results revealed clear associations with poor prognosis of patients, in the case of LOH at D3S1260 and D3S3697
(P¼0.005 and 0.005, respectively). According to our data, potential repressors for telomerase may be located in chromosome 3p.
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Lung cancer is one of the most lethal types of cancer to acquire, as
reflected in a 5-year survival rate of only 14%. The high mortality
rate for lung cancer results, at least in part, from the absence of
standard clinical procedures for diagnosis of the disease at early
and more treatable stages compared to other cancers. Molecular
genetic studies have shown that mutations in proto-oncogenes and
tumour-suppressor genes (TSGs) are critical in the multi-step
development and progression of lung tumours. Inactivation of
TSGs is by far the most common mutational event documented
during lung tumorigenesis (Wiest et al, 1997). In this context,
losses of heterozygosity (LOHs) on the short arm of chromosome 3
have been frequently reported in tumours from different origin,
including lung tumours. In fact, allele loss involving chromosome
3p has been described as one of the most frequent and earliest
known genetic events in lung cancer pathogenesis and it is thought
that this may affect several potential TSG regions (Kok et al, 1997;
Wistuba et al, 2000.
A number of genes that map on 3p have been proposed as
candidates to TSGs of importance in the lung cancer process. One
candidate is FHIT at 3p14.2, which undergoes frequent hemizygous
and occasional homozygous deletion in lung cancer cells and
encodes a dinucleoside hydrolase (Sozzi et al, 1996). Moreover, the
reduced expression of the DNA mismatch repair gene hMLH1
(3p21) has been correlated with allelic imbalance on chromosome
3p in non-small-cell lung carcinomas, and an association between
hMLH1 reduced expression and nodal metastasis in squamous cell
carcinoma of the lung has been observed (Xinarianos et al, 2000).
In addition, the 3p21.3 region has also been extensively examined
for putative TSGs, particularly at a 600-kb region homozygously
deleted in SCLC cell lines (Wei et al, 1996). More recently, a novel
gene encoding a 1755-amino-acid polypeptide has been isolated at
3p22-21.3 and aberrant transcription of this gene, designated
DLEC1 (deleted in lung and oesophagus cancer 1), may be involved
in carcinogenesis of the lung (Daigo et al, 1999).
In the last few years, acquired loss of the entire or parts of the
short arm of chromosome 3 has been considered, by a few authors,
in relationship to the lack of regulation of telomerase (Ohmura
et al, 1995; Horikawa et al, 1998). In renal cell carcinomas, the
presence of at least two genes with regulatory function on the
expression of telomerase has been suggested (Mehle et al, 1998).
Also, deletion analysis of nonrepressed segregant monochromo-
some 3 hybrids, in human breast cancer cells, indicated two
regions on 3p (3p21.3–p22 and 3p12–21.1), where telomerase
regulator genes may be located (Cuthbert et al, 1999).
Considering that 3p deletions and telomerase reactivation are
two of the most frequent alterations described in relation to lung
carcinogenesis, and that there is no report examining both
alterations in non-small-cell lung cancer (NSCLC), in this work
we have analysed LOH at different 3p loci in relationship to
telomerase activity in 66 non-small-cell lung carcinomas obtained
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sfrom patients who had suffered potentially curative surgery. Also,
we have evaluated the prognostic implications for both molecular
markers.
MATERIALS AND METHODS
Patients and tumour samples
In all, 66 freshly resected lung carcinoma samples were obtained
from 66 patients who underwent surgery between 1995 and 2000 at
the San Carlos Hospital in Madrid. This study was approved by the
Ethical Committee from the Hospital, and informed consent from
patients was obtained prior to investigation. Of the 66 patients,
four were female and 62 were male, with an average age of
63.5379.39 years. The median follow-up period for patients was 24
months (range 3–61 months). After surgical resection, samples
were immediately frozen and were kept at  801C until used.
Molecular analyses were performed in samples containing 480%
tumour cells. In all cases, nontumour tissues selected from
macroscopically normal areas of surgical specimens were used as
controls. Tumours were staged pathologically using the tumour
node metastasis (TNM) system (Mountain, 1986) and consisted of
26 TNM Stage I tumours, six TNM II tumours, 26 IIIA tumours,
seven TNM IIIB tumours, and one TNM Stage IV tumour.
Therefore, 58 patients, who had stage I, II or IIIA tumours, were
subjected to curative surgery, whereas only a biopsy was taken
from patients who suffered from more extensive disease. Accord-
ing to the World Health Organisation criteria, 39 tumours were
squamous cell carcinomas (SCC); 26 were adenocarcinomas (AC);
and one was large-cell undifferentiated carcinoma (LCUC). The
histological classification of tumours was established according to
previous criteria (Sobin, 1982). Thus, 17 tumours were well
differentiated; 31 moderately; and 18 poorly differentiated.
Analysis of 3p LOHs
Genomic DNA was isolated from tumour and nontumour tissues
as described previously (Blin and Stafford, 1976). DNA samples
were amplified using polymerase chain reaction (PCR) and
analysed for LOH on chromosome 3p using the five different
polymorphic human dinucleotide repeat DNA markers (D3S1619
at 3p22.2, D3S3623 at 3p22.1, D3S1260 at 3p21.33, D3S3697 at
3p14.3, and D3S3722 at 3p21.2) previously reported (Cuthbert et al,
1999). Sequences for these markers were obtained from the
National Centre for Biotechnology Information (NCBI) molecular
databases. The relative positions of DNA microsatellite markers on
3p are indicated in Figure 1. PCR was performed in a
Thermocycler (Gene Amp PCR System 2400; Perkin-Elmer,
Norwalk, CT, USA) and was carried out in a 20ml volume
containing 100ng of genomic DNA; 0.5mM of upstream and
downstream primers; 0.2mM of each deoxynucleoside tripho-
sphate; 10mM Tris-HCl, pH 8.3; 50mM KCl; 2.5mM MgCl2; and
0.5U of Taq Gold DNA polymerase (Ecogen, SRL, Spain). PCR
conditions were as follow: initial denaturation at 951C for 10min;
35 cycles at 951C for 20s, at 551C for 20s, and at 721C for 30s. The
final extension was at 721C for 7min. After amplification, PCR
products were resolved on an ABI 377 Sequencer and analysed by
Genescan software (Applied Biosystems, USA). For informative
cases, allelic loss was scored if one allele was significantly
decreased in tumour DNA (450%) compared to the same allele
in normal control DNA.
Evaluation of telomerase activity
Telomerase activity in paired normal and tumour tissues was
evaluated as previously published (Gonza ´lez-Quevedo et al, 2000),
using a Telomerase PCR ELISA Kit from Roche (Roche Molecular
Biochemicals, Germany). The method is an extension of the
original Telomeric Repeat Amplification Protocol (TRAP) (Kim
et al, 1994). Briefly, tissue samples were lysed in ice-cold buffer for
30min. In the first step, a volume of cell extract containing 6mgo f
total proteins was incubated with a biotin-labelled synthetic
telomerase-specific primer, and under established conditions the
telomerase present in cellular extracts adds telomeric repeats
(TTAGGG) to the 30 end of the primer. Next, in the second step,
these elongation products were amplified by PCR using specific
primers. An aliquot of the PCR products was denatured,
hybridised to a digoxigenin-labelled, telomeric repeat-specific
probe, and bound to a streptavidin-coated microtitre plate. The
immobilised PCR products were then detected with an antibody
against digoxigenin that is conjugated to peroxidase (anti-DIG-
POD). Finally, the probe was visualised by virtue of peroxidase-
metabolising TMB to form a coloured reaction product, and
semiquantified photometrically (450nm). Considering that the
cutoff for TRAP-ELISA negativity corresponds to OD450nm o0.2,
all samples showing OD450nm 40.2 were judged as telomerase
activity positive. As positive control, we used an extract of the
telomerase embryonic kidney cell line 293, and negative controls
were prepared in each case by treating cell extracts with RNase
(DNase-free). Moreover, to avoid the effect of Taq polymerase
inhibitors present in the tissue extracts, we estimated the activity
of telomerase by serial dilutions of each extract as described
previously (Kim et al, 1994).
Statistical analysis
Both 3p deletions and telomerase activity were assessed
for potential associations with a number of clinicopathologic
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Figure 1 Diagram of chromosome 3p showing the microsatellite
markers used in the LOH analysis. Genetic markers are listed in descending
order from telomere to centromere on its approximate citogenetic
(ideogram) positions. The positions of the DLEC1, RASSF1, FHIT, and
DUTT1 genes are also shown.
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histology and differentiation grade of the primary tumours.
Moreover, possible associations between the telomerase activity
of tumours and LOHs at the different markers considered were
evaluated. The relationship between categorical variables was
assessed using the w
2 test. A P-value o0.05 was judged to be
significant. Distributions of disease-free survival (DFS) were
estimated with the Kaplan–Meier method, and comparisons were
made with log-rank statistics. Results were considered significant
for P-values o0.05. For survival analysis, only patients who had
undergone potentially curative surgery (patients with TNM stages
I–IIIA tumours) were considered. Thus, the number of patients
included in the survival study was 58. Analysis was performed
using windows SPSS version 11.0 software.
RESULTS
Loss of heterozygosity analyses were performed in 66 cases of
NSCLC. In addition, the normal bronchial tissue from each case
was tested simultaneously as a control. Five microsatellite markers
mapping on chromosome 3p were chosen to evaluate LOH in the
DNAs from all of the samples described in Materials and Methods
section. According to our data, the heterozygosity rate for DNA
markers tested here was an average of 80% or greater.
Allelic losses on 3p were recorded in 66.7% (44 out of 66) of
tumours. Results for individual markers revealed that D3S1619
represented the most frequently altered locus since, only
considering informative cases, 20 of 61 tumours (32.7%) showed
LOH at this chromosome locus. Loss of heterozygosity frequency
for the other markers investigated here revealed that 20.7, 20, 24.2,
and 24.2% of informative cases showed deletions at D3S3623,
D3S1260, D3S3697, and D3S3722, respectively. In relation with
clinico-pathological variables, we did not find any significant
correlation with the 3p deletions investigated in this work (data
not shown).
Telomerase activity was positive in 55 (83.3%) of 66 NSCLC
tissue specimens analysed and negative in 11 (16.7%) cases. The
relationship between telomerase activity and clinical and
pathologic features is summarised in Table 1. The mean ages at
surgery, sex, tumour stage, and histology were not different
between the two groups. However, telomerase activity was
significantly correlated with poor differentiation of cancers
(Table 1).
When we studied the possible associations between LOHs on 3p
and telomerase reactivation, our data revealed a significant
correlation with LOH on D3S3697 (3p14.3) (P¼0.040). In fact,
all of the tumours showing LOH at this locus were positives for
telomerase activity (Table 2). As it can be also observed in Table 2,
this analysis indicated a borderline association between D3S1619
(3p22.2) or D3S1260 (3p21.33) deletions and positivity for
telomerase. Moreover, 100% of samples showing LOH at
D3S1260 had been classified in the group of telomerase-positive
cases.
Next, we performed a survival analysis for each one of the
variables evaluated in this work. Thus, such as it had been
previously reported (Gonza ´lez-Quevedo et al, 2002), the Kaplan
and Meier survival curves for patients with NSCLC demonstrated
that patients with telomerase-positive tumours survived for a
shorter period than those with telomerase-negative cancers
(P¼0.04).
In relation to 3p deletions, survival studies indicated a
diminished DFS time in patients affected by tumours showing
this molecular abnormality, but differences were not statistically
significant (data not shown). Interestingly, when survival impact
was evaluated individually for each one of the DNA markers, only
considering informative cases, our results revealed clear associa-
tions with poor prognosis of patients in the case of LOH at
D3S1260 (3p21.33) and D3S3697 (3p14.3) (P¼0.005 and 0.005,
respectively) (Figures 2 and 3).
DISCUSSION
Deregulation of telomerase expression has been directly linked to
human diseases, including cancer. The expression of telomerase is
suppressed in most normal human somatic cells, but is reactivated
during tumorigenesis. This reactivation seems to arrest the normal
loss of telomeric DNA incurred as somatic cells divide. Since
Table 1 Telomerase activity and clinico-pathological variables
Telomerase activity
Variable No of cases (+) (%) ( )( % ) P-value
Age 66 63.7879.32 62.27710.12 0.630
Gender
Males 62 53 (85.4) 9 (14.6) 0.126
Females 4 2 (50) 2 (50)
Tumour stage
I 26 20 (76.9) 6 (23.1) 0.526
II 6 5 (83.3) 1 (16.7)
IIIA 26 24 (92.3) 2 (7.7)
IIIB 7 5 (71.4) 2 (28.6)
IV 1 1 (100) (0)
Histology
a
SCC 39 32 (82) 7 (18) 0.871
AC 26 22 (84.6) 4 (15.4)
LCUC 1 1 (100) 0 (0)
Differentiation
Well 17 11 (64.7) 6 (35.3) 0.018
Moderate 31 26 (83.8) 5 (16.2)
Poor 18 18 (100) 0 (0)
aSCC, squamous cell carcinoma; AC, adenocarcinoma; LCUC, large-cell undiffer-
entiated carcinoma.
Table 2 Relationship between telomerase activity and losses of
heterozygosity on the different markers considered
Telomerase activity
Locus No of cases (+) (%) ( )( % ) P-value
D3S1619
LOH (+) 20 14 (70) 6 (30) 0.092
LOH ( ) 41 36 (87.8) 5 (12.2)
D3S3623
LOH (+) 11 7 (63.6) 4 (36.4) 0.112
LOH ( ) 42 36 (85.7) 6 (14.3)
D3S1260
LOH (+) 12 12 (100) 0 (0) 0.087
LOH ( ) 48 38 (79.2) 10 (20.8)
D3S3697
LOH (+) 16 16 (100) 0 (0) 0.040
LOH ( ) 36 28 (77.8) 8 (22.2)
D3S3722
LOH (+) 16 12 (75) 4 (25) 0.401
LOH ( ) 39 32 (82.1) 7 (17.9)
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scontinual loss of telomeric DNA is predicted to eventually limit cell
proliferation, activation of telomerase in cancer cells may be an
important step in the acquisition of cell immortalisation, which
occurs during tumour progression (Counter et al, 1998; Meyerson,
2000). The mechanisms involved in telomerase regulation are still
far from being fully established (Cong et al, 2002). Thus,
identification of transcriptional repressors and tumour-specific
activators of telomerase subunits should have considerable impact
on the understanding of cellular senescence and immortalisation.
Non-small-cell lung cancer represents one of the most frequent
fatal malignancies in the world. Chromosome 3p deletions have
been described as one of the most frequent genetic events in lung
cancer pathogenesis and it is though that may affect several
potential TSG regions (Kok et al, 1997; Wistuba et al, 2000).
During the last few years, several authors have reported
potential associations between telomerase reactivation and 3p
deletions. Thus, restoration of the cellular senescence program by
chromosome 3 has been associated with repression of telomerase
function in renal cell carcinoma (Ohmura et al, 1995). Moreover, it
has been suggested that a senescence-inducing gene on chromo-
some 3 controls hEST2/hTERT gene expression either directly or
indirectly, and support the notion that hEST2/hTERT is the major
determinant of telomerase enzymatic activity in human cells
(Horikawa et al, 1998). More recently, a strong repression of
telomerase was observed following transfer of human chromosome
3 into human breast cancer cells (Cuthbert et al, 1999). Authors of
this work identified two regions on the short arm of chromosome 3
(3p21.3-p22 and 3p12-21.1) where telomerase regulator genes may
be located.
Considering the importance of telomerase reactivation and 3p
deletions in NSCLC pathogenesis and, on the basis of previous
reports, we have investigated possible associations between both
molecular markers in non-small-cell lung tumours obtained by
surgery from patients affected by this pathology. Losses of
heterozygosity on 3p have been evaluated analysing microsatellite
markers that map on the regions previously reported as important
for repressing telomerase (Cuthbert et al, 1999). The validity of the
five DNA markers used here for 3p deletion investigation was
corroborated. Thus, our data indicated that the heterozygosity rate
for these microsatellite markers was an average of 80% or greater
in all cases.
Almost 70% of the tested samples showed 3p deletion in at least
one of the loci considered. In spite of these results agreeing with
the data previously reported by other authors (Mitsudomi et al,
1996), other studies show higher rates of genetic losses in the
chromosome 3p region in lung cancer. Thus, Wistuba et al (2000)
detected one or more regions of 3p allele loss in nearly all lung
cancer cell lines and in 97% of all resected primary lung tumours.
According to these authors, 3p deletions progress in frequency and
in size with increasing severity of histopathological changes. The
differences in 3p LOH incidences could be attributed to the
histological characteristics of tumours. Thus, differences in the
allelic loss and mutation patterns have been reported previously
between squamous and adenocarcinomas, suggesting that more
genetic changes accumulate during tumorigenesis in squamous cell
carcinomas than in adenocarcinomas (Sato et al, 1994). This fact
may be related to smoking damage (Gazdar and Minna, 1997).
However, no association between 3p LOH and smoking exposure
was detected in our resected lung carcinoma cases.
On the other hand, our results for telomerase indicated that
83.3% of tumours showed positive activity. These incidences are
also similar to that obtained in other previous works (Taga et al,
1999). Furthermore, according to our results, this molecular
parameter represented a poor prognosis indicator in NSCLC. In
fact, all recurrences were detected in the group of patients with
positive telomerase tumours.
When the relationship between telomerase reactivation and 3p
deletions at the different loci considered in the present study was
established, results obtained showed a significant correlation
between telomerase activity and LOH at D3S3697 (mapping at
3p14.3). Moreover, borderline associations were found for LOH at
D3S1619 or D3S1260 (located at 3p22.2 and 3p21.33, respectively)
and telomerase-positive cases. Interestingly, LOH on two of the
three DNA markers was present only in telomerase-positive
samples (D3S3697 and D3S1260) and, such as it can be observed
in the Results section, survival studies demonstrated the im-
portance of LOHs at these levels in poorer patient prognosis.
Therefore, according to our results, the potential repressors for
telomerase may be located in chromosome 3p, and to our
knowledge this is the first work in which such association is
investigated ‘in vivo’ in NSCLC tumours. Although the nature of 3p
genes implicated in negative regulation of telomerase remains
unknown, according to our results, possible TSGs may be involved
as candidates. In fact, several genes with importance in lung
development and bronchial hyperplasia are located near to the
chromosome region where D3S3697 maps (3p14.3) (Figure 1).
Between these, two suppressor genes have been proposed. Thus,
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Months after surgery
D3S1260 (–) (N = 41)
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Figure 2 Correlation between LOH at D3S1260 and DFS in patients
with NSCLC. N: number of cases; ( ): LOH negative; (þ): LOH positive.
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Figure 3 Kaplan–Meier survival curves for LOH at D3S3697 in NSCLC
patients. N: number of cases; ( ): LOH negative; (þ): LOH positive.
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sFHIT (at 3p14.2), which undergoes frequent deletion in lung
cancer cells and encodes a dinucleoside hydrolase (Sozzi et al,
1996), could be affected by LOH at D3S3697. On the other hand,
DUTT1 (3p12–13), coding for a receptor with a domain structure
of the neural-cell adhesion family, could also be considered. This
gene is widely expressed and has been implicated in the guidance
and migration of axons myoblasts, and leukocytes in vertebrates.
Mice experiments demonstrated that deletion of the 3p region
where DUTT1 maps was associated with bronchial epithelial
abnormalities including hyperplasia (Xian et al, 2001).
Moreover, a novel gene has been mapped in 3p22–21.3
(Figure 1). This gene, called DLEC1 (deleted in lung and
oesophagus cancer 1) (Daigo et al, 1999) has been identified as a
candidate TSG, and it has been suggested that it may be involved
in carcinogenesis of the lung, oesophagus, and kidney. Our results
suggest that deletions in D3S1619 or D3S1260 could be related to
LOHs affecting this gene.
Finally, in the group of TSGs on 3p that may be considered as
candidates to negative regulation of telomerase, RASSF1 would be
included (Figure 1). This putative tumour suppressor identified at
3p21.3 has recently been analysed in relation to NSCLC. Silencing
of this gene occurs mainly by promoter methylation (Endoh et al,
2003; Kim et al, 2003), but gene deletion has also been described as
a potential mechanism that contributes to lung tumorigenesis
(Kuroki et al, 2003).
Therefore, results included in this work corroborate ‘in vivo’
previous data obtained ‘in vitro’, suggesting the existence on 3p of
one or several genes that participate in telomerase-negative
regulation. However, according to gene databases, a wide group
of genes on 3p could be related to telomerase regulation, and
future and exhaustive studies examining deletions affecting
different regions of each one of these genes in relation to
telomerase activity are necessary in order to elucidate mechanisms
involved in telomerase regulation. In fact, identification of
telomerase repressors should have considerable impact on the
understanding of cellular immortalisation and cellular senescence,
as well as on cancer therapeutic based on the use of telomerase
inhibitors.
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